Cirius Therapeutics (fka Octeta Therapeutics) is a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease. Its lead product is MSDC-0602K, a second‑generation insulin sensitizer being evaluated for non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company is actively enrolling patients in the Emminence Phase 2b clinical trial to evaluate MSDC-0602K. Cirius plans to use the proceeds from its recent financing to complete the ongoing Emminence trial. The company is led by newly appointed CEO Bob Baltera, CMO Howard Dittrich, M.D., and CBO Brian Farmer. Cirius is based in Kalamazoo, Michigan and San Diego, California and completed a Series A financing of up to $40m.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2017